Collectively, our findings make a new contribution to the study of altered lipid metabolism in PCa and reveals DECR2 as a major modulator of cell cycle progression and lipid metabolism, and an exciting novel candidate for therapeutic targeting. This evidence concerns the gene DECR2 and posterior cortical atrophy.